NHMRC Clinical Trials Centre - The University of Sydney

Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye

    Sydney, November 7 (ots/PRNewswire) - In the Lancet, on Tuesday November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA.

    - First lipid modifying agent shown to reduce the need for treatment of the leading causes of blindness and deteriorating vision in patients with type 2 diabetes

    - Reduces need for laser treatment in patients with and without known diabetic retinopathy

    - Significantly decreases progression of diabetic eye disease

    If you are interested in knowing more about this breaking news and in getting additional information on the management of microvascular complications in type 2 diabetes, we are pleased to invite you to visit "the Field Study Investigators Website", where you will have the opportunity to login to the Webcast of the press conference.

    Please click below: http://www.thefieldtrial.org

ots Originaltext: NHMRC Clinical Trials Centre - The University of Sydney
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Media Contact: Beth Quinlivan, University of Sydney, Ph:
+61-2-9036-6528, Mob: +61-0-419-229-134, bquinlivan@med.usyd.edu.au



Weitere Meldungen: NHMRC Clinical Trials Centre - The University of Sydney

Das könnte Sie auch interessieren: